Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Evotec : to Attend Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 06:38pm CEST

By a News Reporter-Staff News Editor at Biotech Week -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced that its management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, USA; 6th German Corporate Conference, Berenberg/Goldman Sachs in Munich, Germany, and Baader Investment Conference, Munich, Germany, and will be attending Goldman Sachs' 7th Annual Biotech Symposium in London, UK, and Bank of America Merrill Lynch Global Healthcare Conference 2017 in London ,UK. Goldman Sachs' 7th Annual Biotech Symposium, London, UK - Date: Friday, 08 September 2017

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG Morgan Stanley 15th Annual Global Healthcare Conference, New York, USA - Date: Monday, 11 September 2017, 04.50 pm EDT (09.50 pm BST, 10.50 pm CEST)

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK - Date: Thursday, 14 September 2017

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG 6th German Corporate Conference, Berenberg/Goldman Sachs, Munich, Germany - Date: Monday, 18 September 2017, 11.00 am CEST (10.00 am BST, 05.00 am EDT)

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG Baader Investment Conference, Munich, Germany - Date: Wednesday, 20 September 2017, 05.15 pm CEST (04.15 am BST, 11.15 am EDT)

- Venue: Munich, Germany

Keywords for this news article include: Biotechnology, Evotec AG (see also Evotec AG).

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
07/09EVOTEC : confirm closing of transaction with Sanofi to accelerate infectious dis..
AQ
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
07/03EVOTEC AG : Evotec Confirm Closing Of Transaction With Sanofi To Accelerate Infe..
AC
07/03EVOTEC : Confirm closing of transaction with sanofi to accelerate infectious dis..
EQ
06/28EVOTEC : achieves second milestone in diabetes alliance with Sanofi
AQ
06/25EVOTEC AG : Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi
AC
06/25EVOTEC : Resolutions of the Annual General Meeting 2018 of Evotec AG
AQ
06/25EVOTEC : Achieves second milestone in diabetes alliance with sanofi
EQ
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/20EVOTEC AG : Resolutions of the Annual General Meeting 2018 of Evotec AG
AC
More news
News from SeekingAlpha
05/31Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research .. 
05/21Celgene teams up with Evotec to discover new cancer treatments 
05/09Evotec's (EVOTF) CEO Werner Lanthaler on Q1 2018 Results - Earnings Call Tran.. 
05/09Evotec AG 2018 Q1 - Results - Earnings Call Slides 
05/09Evotec AG reports Q1 results 
Financials (€)
Sales 2018 353 M
EBIT 2018 48,4 M
Net income 2018 34,2 M
Debt 2018 70,3 M
Yield 2018 -
P/E ratio 2018 67,77
P/E ratio 2019 47,68
EV / Sales 2018 6,85x
EV / Sales 2019 6,29x
Capitalization 2 350 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,9 €
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG17.96%2 745
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147